New Smart Hypoglycemic Drugs Novozymes Launches in China

Lowering blood sugar is also prone to hypoglycemia, which is a contradiction that has always existed in the course of diabetes treatment. The new diabetes drug Novozymes (Lilaglutide Injection), officially launched in the country, will break through this treatment "difficulty." It is reported that Novozymes is the world’s first human glucagon-like peptide analogue (GLP-1 analogue) and has been marketed in more than 30 countries around the world.

Yang Wenying, director of the Department of Endocrinology at the China-Japan Friendship Hospital of the Ministry of Health, led the registration study of the drug in China. She pointed out that GLP-1 is a hormone in the gastrointestinal tract that stimulates insulin secretion, and it is only activated when the glucose level is elevated. If the blood glucose is normal, injection of more GLP-1 will not work. The hypoglycemic principle allows Novozymes to reduce hypoglycemia while reducing blood sugar. In addition, the study also showed that Novozymes can also reduce the patient's weight and blood pressure, and also have a positive effect on reducing the risk of cardiovascular disease, and also have protective effects on pancreatic islet β cells.